- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00943553
A Randomized Study of Epigenetic Priming Using Decitabine With Front Line Induction Chemotherapy Compared With Immediate Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects
April 10, 2015 updated by: Eisai Inc.
A Randomized Study of Epigenetic Priming Using Decitabine With Front Line Induction Chemotherapy Compared With Immediate Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects.
The purpose of this study is to evaluate the efficacy and safety of decitabine when used before chemotherapy to treat leukemia in pediatric patients.
The study will also evaluate the ways decitabine is affected or changed when used in the human body.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Study Type
Interventional
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
New Delhi, India, 110085
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 year to 16 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Males and females, age 1 to16 years, inclusive
- Females of childbearing potential must have a negative serum beta human chorionic gonadotropin (β-hCG) at Visit 1 (Screening) and a negative urine pregnancy test prior to starting study drugs (Visit 2). Female subjects of childbearing potential must agree to be abstinent or to use a highly effective method of contraception (eg, condom + spermicide, condom + diaphragm with spermicide, intrauterine devise (IUD), or have a vasectomised partner) for at least one menstrual cycle prior to starting study drug(s) and throughout the longer of either Core Study period or 30 days after the last dose of study drug. Those females using hormonal contraceptives must also be using an additional approved method of contraception (as described previously).
- Sexually mature male patients who are not abstinent or have not undergone a successful vasectomy, who are partners of women of childbearing potential must use, or their partners must use a highly effective method of contraception (eg, condom + spermicide, condom + diaphragm with spermicide, IUD) starting for at least one menstrual cycle prior to starting study drug(s) and throughout the entire study period and for 30 days (longer if appropriate) after the last dose of study drug. Those with partners using hormonal contraceptives must also be using an additional approved method of contraception (as described previously).
- Diagnosis of acute myelogenous leukemia (AML)(bone marrow or peripheral blood blasts ≥ 20%)
- Adequate cardiac function as defined by an echocardiogram or multiple gated acquisition (MUGA) scan demonstrating an ejection fraction within normal limits
- Are willing and able to comply with all aspects of the protocol
- Provide written informed consent from subject's guardian or legally authorized representative and child assent (if applicable)
Exclusion Criteria:
- Females who are pregnant (positive β-hCG test) or lactating
- History of chronic myelogenous leukemia (CML) [t(9;22)]
- Acute promyelocytic leukemia (M3 subtype in French-American-British [FAB] classification).
- Known central nervous system (CNS) leukemia
- AML associated with congenital syndromes such as Down syndrome, Fanconi anemia, Bloom syndrome, Kostmann syndrome, or Diamond Blackfan anemia
- White blood cell (WBC) count > 40,000/mm3
- Serum creatinine > 2.5 mg/dL
- Alanine aminotransferase (ALT) > 5 x upper limit of normal (ULN) and/or total bilirubin > 3 x ULN
- Prior chemotherapy (other than hydroxyurea) or radiation therapy for AML
- Known to be human immunodeficiency virus (HIV) positive
- Any history of or concomitant medical condition that, in the opinion of the Investigator, would compromise the subject's ability to safely complete the study
- The Investigator believes the subject to be medically unfit to receive the study drug or unsuitable for any other reason.
- Subject with hypersensitivity to decitabine, daunorubicin, or cytarabine
- Has participated in a drug trial in the last 4 weeks
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
|
Arm A - 12 days (5 days of intravenous (IV) decitabine 20 mg/m^2 followed by 7 days of induction chemotherapy with IV daunorubicin 45 mg/m^2 and cytarabine 100 mg/m^2/day)
Other Names:
|
Experimental: 2
|
Arm B - 7 days (7 days of induction chemotherapy with IV daunorubicin 45 mg/m^2 and cytarabine 100 mg/m^2/day only)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Primary Endpoint (Core Component): Complete Remission (CR) Rate as defined by International Working Group - 2003 criteria
Time Frame: ~ 2 years
|
~ 2 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Secondary Endpoint (Core Component): Methylation of DNA following decitabine therapy.
Time Frame: Until Week 3 after chemotherapy
|
Until Week 3 after chemotherapy
|
Secondary Endpoint (Core Component): Time to platelet recovery (≥ 100,000/mm3) and time to neutrophil recovery (absolute neutrophil count [ANC] ≥ 1000/mm3) following induction chemotherapy
Time Frame: Until ~ 4 weeks after last dose of induction chemotherapy
|
Until ~ 4 weeks after last dose of induction chemotherapy
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Peter Tarassoff, MD, Eisai Inc.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2010
Primary Completion (Actual)
August 1, 2011
Study Registration Dates
First Submitted
July 21, 2009
First Submitted That Met QC Criteria
July 21, 2009
First Posted (Estimate)
July 22, 2009
Study Record Updates
Last Update Posted (Estimate)
April 13, 2015
Last Update Submitted That Met QC Criteria
April 10, 2015
Last Verified
April 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- E7373-G000-201
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Myelogenous Leukemia (AML)
-
Eisai Inc.TerminatedPediatric Acute Myelogenous Leukemia (AML)United States, Canada, Australia
-
Maxinovel Pty., Ltd.RecruitingAcute Myelogenous Leukemia (AML)Australia
-
AbbVieGenentech, Inc.CompletedAcute Myeloid Leukemia | AML | Acute Myelogenous Leukemia
-
Merck Sharp & Dohme LLCTerminatedAcute Myelogenous Leukemia (AML)
-
Maxinovel Pty., Ltd.Recruiting
-
AbbVieGenentech, Inc.CompletedAML | Acute Myelogenous LeukemiaUnited States, Australia, Germany, Italy
-
Emory UniversityTeva Pharmaceuticals USATerminated
-
Sidney Kimmel Cancer Center at Thomas Jefferson...University of PennsylvaniaCompleted
-
Ascenta TherapeuticsThe Leukemia and Lymphoma SocietyTerminated
-
Beth Israel Deaconess Medical CenterDana-Farber Cancer Institute; National Institutes of Health (NIH); Medivation... and other collaboratorsActive, not recruitingAML | Acute Myelogenous LeukemiaUnited States
Clinical Trials on decitabine Induction Chemotherapy
-
European Organisation for Research and Treatment...Janssen Pharmaceuticals; Gruppo Italiano Malattie EMatologiche dell'AdultoActive, not recruitingAcute Myeloid Leukemia (AML)Germany, Belgium, Netherlands, Italy, France, Croatia, Bulgaria, Lithuania, Portugal
-
Sun Yat-sen UniversityRecruiting
-
Clinica Universidad de Navarra, Universidad de...CompletedAdenocarcinoma | Gastrointestinal Neoplasms | Gastric Cancer | Surgery | Effects of ChemotherapySpain
-
First Affiliated Hospital, Sun Yat-Sen UniversityRecruitingLocally Advanced Nasopharyngeal CarcinomaChina
-
Guiyang Medical UniversitySun Yat-sen University; The Affiliated Cancer Hospital of Xiangya School of...Unknown
-
Institute of Oncology LjubljanaRecruitingLocally Advanced Rectal CancerSlovenia
-
Centre Hospitalier Universitaire de Saint EtienneCompleted
-
Centre Hospitalier Universitaire de Saint EtienneInstitut de Cancérologie de la LoireRecruitingAcute Myeloid LeukemiaFrance
-
AHEPA University HospitalCompletedMortality | Patient Outcome Assessment | Morbidity
-
Sun Yat-sen UniversitySun Yat-Sen Memorial Hospital of Sun Yat-Sen University; Fifth Affiliated Hospital... and other collaboratorsNot yet recruiting